1. Home
  2. VRAX vs ONCO Comparison

VRAX vs ONCO Comparison

Compare VRAX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • ONCO
  • Stock Information
  • Founded
  • VRAX 2013
  • ONCO 2018
  • Country
  • VRAX United Kingdom
  • ONCO United States
  • Employees
  • VRAX N/A
  • ONCO N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ONCO Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • ONCO Health Care
  • Exchange
  • VRAX Nasdaq
  • ONCO Nasdaq
  • Market Cap
  • VRAX 7.3M
  • ONCO 9.4M
  • IPO Year
  • VRAX 2022
  • ONCO 2022
  • Fundamental
  • Price
  • VRAX $1.66
  • ONCO $0.60
  • Analyst Decision
  • VRAX
  • ONCO
  • Analyst Count
  • VRAX 0
  • ONCO 0
  • Target Price
  • VRAX N/A
  • ONCO N/A
  • AVG Volume (30 Days)
  • VRAX 236.4K
  • ONCO 10.5M
  • Earning Date
  • VRAX 02-05-2025
  • ONCO 12-10-2024
  • Dividend Yield
  • VRAX N/A
  • ONCO N/A
  • EPS Growth
  • VRAX N/A
  • ONCO N/A
  • EPS
  • VRAX N/A
  • ONCO N/A
  • Revenue
  • VRAX $84,872.00
  • ONCO $1,870,605.00
  • Revenue This Year
  • VRAX $5,169.18
  • ONCO N/A
  • Revenue Next Year
  • VRAX $66.97
  • ONCO N/A
  • P/E Ratio
  • VRAX N/A
  • ONCO N/A
  • Revenue Growth
  • VRAX 7.03
  • ONCO N/A
  • 52 Week Low
  • VRAX $0.60
  • ONCO $0.32
  • 52 Week High
  • VRAX $9.00
  • ONCO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 42.25
  • ONCO 51.04
  • Support Level
  • VRAX $1.56
  • ONCO $0.51
  • Resistance Level
  • VRAX $1.86
  • ONCO $0.70
  • Average True Range (ATR)
  • VRAX 0.19
  • ONCO 0.09
  • MACD
  • VRAX -0.04
  • ONCO 0.03
  • Stochastic Oscillator
  • VRAX 26.31
  • ONCO 34.45

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: